What is CDG Biotech?
CDG Biotech Corp operates as a specialized manufacturer in the IVD space, focusing on the development of automated esoteric diagnostic solutions. The company is recognized for its commitment to operational efficiency, providing laboratories with user-friendly technology designed to mitigate labor costs while simultaneously elevating diagnostic quality. Their flagship innovation, the Q-strip, utilizes chemiluminescent solid-phase immunoassay technology to deliver precise quantitative measurements of hormones and biomarkers. With ISO13485:2016 certification and FDA registration, CDG Biotech maintains rigorous manufacturing standards, enabling a seamless transition for clinical and veterinary laboratories from manual processes to high-throughput automated assays. This focus on equipment ROI and diagnostic precision positions the firm as a pivotal player in the global laboratory automation market.
How much funding has CDG Biotech raised?
CDG Biotech has raised a total of $41K across 1 funding round:
Debt
$41K
Debt (2021): $41K with participation from PPP
Key Investors in CDG Biotech
PPP
Public-Private Partnership
What's next for CDG Biotech?
Looking ahead, the infusion of capital will likely be directed toward scaling the production of the Q-strip platform and expanding the company's international distribution network. Given the current Series B/C stage, the focus will shift toward aggressive market penetration and the potential development of next-generation diagnostic assays. By optimizing its supply chain and deepening its presence in key geographic regions, CDG Biotech is poised to capitalize on the increasing demand for automated, high-quality diagnostic tools. The company's ability to maintain high regulatory standards while scaling operations will be the primary determinant of its long-term success in the evolving healthcare technology landscape.
See full CDG Biotech company page
